Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) insider Benjamin T. Dake sold 3,325 shares of the company's stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $31.97, for a total value of $106,300.25. Following the sale, the insider now owns 1,291 shares of the company's stock, valued at $41,273.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Aerovate Therapeutics Stock Performance
AVTE stock opened at $29.12 on Thursday. Aerovate Therapeutics, Inc. has a 1 year low of $9.41 and a 1 year high of $32.42. The firm has a market cap of $811.37 million, a P/E ratio of -10.11 and a beta of 1.23. The stock has a 50-day simple moving average of $22.98 and a 200-day simple moving average of $18.19.
Institutional Investors Weigh In On Aerovate Therapeutics
Large investors have recently modified their holdings of the stock. UBS Group AG acquired a new stake in shares of Aerovate Therapeutics in the third quarter valued at about $26,000. Tower Research Capital LLC TRC grew its stake in Aerovate Therapeutics by 136.2% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,702 shares of the company's stock valued at $55,000 after purchasing an additional 1,558 shares in the last quarter. Citigroup Inc. grew its stake in Aerovate Therapeutics by 1,351.5% during the 2nd quarter. Citigroup Inc. now owns 3,324 shares of the company's stock valued at $57,000 after purchasing an additional 3,095 shares in the last quarter. BNP Paribas Arbitrage SNC acquired a new stake in Aerovate Therapeutics during the 3rd quarter valued at approximately $66,000. Finally, Wells Fargo & Company MN grew its stake in Aerovate Therapeutics by 156.7% during the 2nd quarter. Wells Fargo & Company MN now owns 4,200 shares of the company's stock valued at $72,000 after purchasing an additional 2,564 shares in the last quarter.
Analyst Upgrades and Downgrades
AI finds its first serious application
From Wall Street Star | Ad
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing.
Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Click here to learn more about the booming eHealth industry
Several equities research analysts have commented on the company. Jefferies Financial Group assumed coverage on Aerovate Therapeutics in a research note on Monday, March 25th. They set a "buy" rating and a $65.00 price target for the company. Wells Fargo & Company restated an "overweight" rating and set a $35.00 price target on shares of Aerovate Therapeutics in a research note on Monday.
View Our Latest Analysis on AVTE
Aerovate Therapeutics Company Profile
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
